KR101490449B1 - 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지 - Google Patents

세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지 Download PDF

Info

Publication number
KR101490449B1
KR101490449B1 KR1020087025460A KR20087025460A KR101490449B1 KR 101490449 B1 KR101490449 B1 KR 101490449B1 KR 1020087025460 A KR1020087025460 A KR 1020087025460A KR 20087025460 A KR20087025460 A KR 20087025460A KR 101490449 B1 KR101490449 B1 KR 101490449B1
Authority
KR
South Korea
Prior art keywords
cells
delete delete
cell
adhesive
placenta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087025460A
Other languages
English (en)
Korean (ko)
Other versions
KR20080110831A (ko
Inventor
샤이 메레츠키
자미 에버먼
오라 버거
Original Assignee
플루리스템 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38522837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101490449(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 플루리스템 리미티드 filed Critical 플루리스템 리미티드
Publication of KR20080110831A publication Critical patent/KR20080110831A/ko
Application granted granted Critical
Publication of KR101490449B1 publication Critical patent/KR101490449B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
KR1020087025460A 2006-03-23 2007-03-22 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지 Active KR101490449B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78476906P 2006-03-23 2006-03-23
US60/784,769 2006-03-23
US84708806P 2006-09-26 2006-09-26
US60/847,088 2006-09-26
PCT/IL2007/000380 WO2007108003A2 (en) 2006-03-23 2007-03-22 Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029038A Division KR101557256B1 (ko) 2006-03-23 2007-03-22 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지

Publications (2)

Publication Number Publication Date
KR20080110831A KR20080110831A (ko) 2008-12-19
KR101490449B1 true KR101490449B1 (ko) 2015-02-05

Family

ID=38522837

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087025460A Active KR101490449B1 (ko) 2006-03-23 2007-03-22 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지
KR1020147029038A Active KR101557256B1 (ko) 2006-03-23 2007-03-22 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147029038A Active KR101557256B1 (ko) 2006-03-23 2007-03-22 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지

Country Status (21)

Country Link
US (2) US20110129447A1 (enExample)
EP (5) EP2010647A4 (enExample)
JP (3) JP5733894B2 (enExample)
KR (2) KR101490449B1 (enExample)
CN (1) CN105296415A (enExample)
AU (1) AU2007228341B2 (enExample)
BR (1) BRPI0709349A2 (enExample)
CA (1) CA2646384C (enExample)
DK (2) DK2626417T3 (enExample)
ES (3) ES2537641T3 (enExample)
HK (1) HK1217513A1 (enExample)
HR (1) HRP20160538T1 (enExample)
HU (1) HUE028796T2 (enExample)
IL (1) IL236213A (enExample)
MX (1) MX2008012085A (enExample)
PL (2) PL2366775T3 (enExample)
PT (3) PT2626417E (enExample)
RU (1) RU2433177C2 (enExample)
SG (1) SG170761A1 (enExample)
SI (1) SI2548951T1 (enExample)
WO (1) WO2007108003A2 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641915B1 (en) 2003-06-27 2016-07-27 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
JP5289970B2 (ja) 2005-12-16 2013-09-11 エシコン・インコーポレイテッド 組織適合性不適合な移植における逆免疫反応を抑制するための組成物および方法
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
CA2646384C (en) * 2006-03-23 2020-03-24 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
PL2089511T3 (pl) * 2006-11-13 2015-02-27 Depuy Synthes Products Llc Rozrost in vitro komórek pochodzących z tkanki pępowinowej wykorzystujących mikronośniki
RS52921B (sr) * 2007-02-12 2014-02-28 Anthrogenesis Corporation Lečenje inflamatornih bolesti upotrebom placentnih matičnih ćelija
JP5162784B2 (ja) * 2007-07-11 2013-03-13 日東電工株式会社 細胞培養基材及びその製造方法並びに細胞培養方法
RU2010109698A (ru) 2007-09-19 2011-09-27 Плуристем Лтд. (Il) Адгезивные клетки жировой ткани или плаценты и их использование в лечебных целях
AU2013267050B2 (en) * 2007-09-19 2016-01-07 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
CA2725637A1 (en) 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
CN105766891A (zh) 2008-08-20 2016-07-20 人类起源公司 改进的细胞组合物及制备所述组合物的方法
EP2334783B1 (en) * 2008-09-02 2016-06-22 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
US20110256108A1 (en) * 2008-09-02 2011-10-20 Moran Meiron Methods of selection of cells for transplantation
US9096827B2 (en) * 2008-09-02 2015-08-04 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
US10557116B2 (en) 2008-12-19 2020-02-11 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
SG174551A1 (en) 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
EP2806023B1 (en) 2009-11-30 2015-09-23 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9757419B2 (en) 2010-05-27 2017-09-12 Pluristem Ltd. Skeletal muscle regeneration using mesenchymal system cells
WO2012030968A1 (en) * 2010-08-31 2012-03-08 Renovocyte, LLC Systemic, allogenic stem cell therapies for treatment of diseases in animals
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP5981947B2 (ja) 2011-03-04 2016-08-31 アル−カタニ, アーメッド・エイチAl−Qahtani, Ahmed H. スキンクリーム
KR101835917B1 (ko) * 2011-03-22 2018-03-07 플루리스템 리미티드 방사선 또는 화학적 손상을 치료하는 방법들
WO2012140519A2 (en) * 2011-04-15 2012-10-18 Pluristem Ltd. Methods and systems for harvesting cells
WO2013070734A1 (en) 2011-11-07 2013-05-16 Chaudhry Hina W Methods of cardiac repair
ITTO20111183A1 (it) * 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
AU2013311289B2 (en) 2012-09-04 2017-11-16 Pluristem Ltd. Methods for prevention and treatment of preeclampsia
CA2882108C (en) 2012-09-06 2016-01-05 Pluristem Ltd. Three dimensional devices for supporting monolayer cell growth and methods of culturing cells therewith
WO2014128634A1 (en) 2013-02-20 2014-08-28 Pluristem Ltd. Gene and protein expression properties of adherent stromal cells cultured in 3d
WO2014141111A1 (en) 2013-03-14 2014-09-18 Pluristem Ltd. Methods for prevention and treatment of graft-versus-host disease
RU2525143C1 (ru) * 2013-03-22 2014-08-10 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук СПОСОБ ЭКСПАНСИИ МОНОНУКЛЕАРНЫХ КЛЕТОК ПУПОВИННОЙ КРОВИ (пкМНК) ex vivo В ПРИСУТСТВИИ МУЛЬТИПОТЕНТНЫХ СТРОМАЛЬНЫХ МЕЗЕНХИМАЛЬНЫХ КЛЕТОК (ММСК)
RU2539750C2 (ru) * 2013-04-09 2015-01-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ оценки иммуносупрессивных свойств мезенхимальных стромальных клеток человека
WO2015004609A2 (en) 2013-07-09 2015-01-15 Pluristem Ltd. Adherent cells from placenta and use thereof in treatment of injured tendons
AU2014296259B2 (en) 2013-07-30 2017-04-27 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
WO2015025059A1 (en) * 2013-08-23 2015-02-26 Fundacion Pública Andaluza Progreso Y Salud Cd105-negative multipotent mesenchymal stromal cells
CN105992816B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
WO2015132729A1 (en) 2014-03-04 2015-09-11 Pluristem Ltd. Systems and methods for growing and harvesting cells
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
US10258652B2 (en) 2014-12-18 2019-04-16 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
IL294058A (en) 2015-03-23 2022-08-01 Pluristem Ltd Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof
WO2016187413A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
RU2628092C1 (ru) * 2016-02-10 2017-08-14 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) Способ получения МСК-ассоциированных недифференцированных гемопоэтических клеток-предшественников с фенотипов CD34+/CD133+
AU2017218143B2 (en) * 2016-02-12 2023-08-03 Cell Care Therapeutics, Inc. Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
US20210205370A1 (en) 2016-02-18 2021-07-08 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
US10851347B2 (en) 2016-06-06 2020-12-01 Pluristem Ltd. Altered adherent stromal cells and methods of producing and using same
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US20200080147A1 (en) * 2017-02-20 2020-03-12 Pluristem Ltd. Methods and compositions for tumor assessment
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
CN110831694A (zh) * 2017-03-31 2020-02-21 细尔琳生物医学公司 生物相容性调整细胞培养基组合物及其用途
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
WO2018198012A1 (en) 2017-04-24 2018-11-01 Pluristem Ltd. Methods and compositions for treating neurological disorders
WO2018199194A1 (ja) * 2017-04-25 2018-11-01 北海道公立大学法人札幌医科大学 間葉系幹細胞の製造方法、間葉系幹細胞の治療効果マーカー及び治療効果判定方法、並びに間葉系幹細胞を含む細胞製剤
IL260253A (en) 2017-07-03 2019-01-31 Pluristem Ltd Methods and compounds for removing adherent cells
WO2019175773A1 (en) 2018-03-12 2019-09-19 Universidade Do Porto Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells
KR102723986B1 (ko) 2018-04-25 2024-10-31 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 생체 이식용 세포 시트 및 그 제조 방법
CA3182658A1 (en) 2020-05-08 2021-11-11 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
WO2022164788A2 (en) * 2021-01-26 2022-08-04 The Trustees Of Indiana University Pharmaceutical compositions and their methods of use
CN112813002B (zh) * 2021-02-07 2022-11-08 天津科技大学 一株耐热短乳杆菌及其后生素制剂的应用
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032179A1 (en) * 2000-12-06 2003-02-13 Hariri Robert J. Post-partum mammalian placenta, its use and placental stem cells therefrom

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5266476A (en) * 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5168085A (en) 1991-05-20 1992-12-01 Corning Incorporated Multi-stage twc system
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5629186A (en) 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
WO1997018299A1 (en) 1995-11-16 1997-05-22 Case Western Reserve University In vitro chondrogenic induction of human mesenchymal stem cells
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6291240B1 (en) * 1998-01-29 2001-09-18 Advanced Tissue Sciences, Inc. Cells or tissues with increased protein factors and methods of making and using same
DE69903800T2 (de) 1998-03-18 2003-10-02 Massachusetts Institute Of Technology, Cambridge Vaskularisierte perfundierte anordnungen für mikrogewebe und mikroorgane
JP4526186B2 (ja) 1998-06-08 2010-08-18 オシリス セラピューティクス，インコーポレイテッド 造血幹細胞を試験管内で維持する方法と組成物
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
WO2000046349A1 (en) * 1999-02-04 2000-08-10 Technion Research & Development Foundation Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
IL145002A0 (en) * 1999-03-10 2002-06-30 Univ Pittsburgh Adipose-derived stem cells and lattices
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
AU4860900A (en) 1999-06-02 2000-12-18 Lifebank Services, L.L.C. Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
WO2001062901A2 (en) 2000-02-26 2001-08-30 Artecel Sciences, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
US6916640B2 (en) * 2000-10-12 2005-07-12 Agency For Science, Technology And Research Multi-layer cell encapsulation for tissue engineering
KR100915483B1 (ko) * 2000-12-06 2009-09-03 로버트 제이 하리리 태반 줄기 세포의 회수 방법
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
ES2545899T3 (es) * 2001-02-14 2015-09-16 Anthrogenesis Corporation Placenta post-parto de mamíferos, su uso y células madre placentarias de la misma
CA2466880A1 (en) * 2001-11-09 2003-05-15 Artecel Sciences, Inc. Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
JP2003180334A (ja) * 2001-12-17 2003-07-02 Japan Science & Technology Corp 三次元高密度細胞培養用モジュール
US7504099B2 (en) 2001-12-27 2009-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of inducing or enhancing connective tissue repair
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20030235563A1 (en) * 2002-04-19 2003-12-25 Strom Stephen C. Placental derived stem cells and uses thereof
US20060172304A1 (en) 2003-02-27 2006-08-03 Elaine Fuchs Method for modulating epithelial stem cell lineage
EP1641915B1 (en) * 2003-06-27 2016-07-27 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US6924458B2 (en) 2003-07-17 2005-08-02 Great Computer Corp. Auxiliary focusing tool for laser marker
EP1756267A2 (en) 2004-05-14 2007-02-28 Becton, Dickinson and Company Stem cell populations and methods of use
DE102004043256B4 (de) * 2004-09-07 2013-09-19 Rheinische Friedrich-Wilhelms-Universität Bonn Skalierbarer Prozess zur Kultivierung undifferenzierter Stammzellen in Suspension
CN103361301A (zh) 2005-03-31 2013-10-23 斯丹姆涅恩有限公司 高度纯化来自羊膜的细胞群
US20100233130A1 (en) * 2006-02-06 2010-09-16 Pluristem Ltd. Method and Apparatus for Maintenance and Expansion of Hematopoietic Stem Cells From Mononuclear Cells
CA2646384C (en) * 2006-03-23 2020-03-24 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
KR101835917B1 (ko) * 2011-03-22 2018-03-07 플루리스템 리미티드 방사선 또는 화학적 손상을 치료하는 방법들

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032179A1 (en) * 2000-12-06 2003-02-13 Hariri Robert J. Post-partum mammalian placenta, its use and placental stem cells therefrom

Also Published As

Publication number Publication date
PT2626417E (pt) 2015-11-16
EP2366775B1 (en) 2015-04-22
MX2008012085A (es) 2009-01-22
PT2366775E (pt) 2015-07-20
BRPI0709349A2 (pt) 2011-07-12
EP2366775A1 (en) 2011-09-21
JP2009531059A (ja) 2009-09-03
PL2366775T3 (pl) 2015-08-31
CA2646384C (en) 2020-03-24
PT2548951E (pt) 2016-06-14
HK1187950A1 (en) 2014-04-17
WO2007108003A2 (en) 2007-09-27
CN105296415A (zh) 2016-02-03
EP3091071B1 (en) 2019-07-03
JP2014088408A (ja) 2014-05-15
DK2366775T3 (en) 2015-06-15
EP2548951A1 (en) 2013-01-23
AU2007228341A1 (en) 2007-09-27
KR101557256B1 (ko) 2015-10-02
HK1217513A1 (zh) 2017-01-13
ES2572214T3 (es) 2016-05-30
EP2010647A4 (en) 2010-05-19
JP5733894B2 (ja) 2015-06-10
ES2537641T3 (es) 2015-06-10
HK1136846A1 (en) 2010-07-09
HK1177759A1 (en) 2013-08-30
SI2548951T1 (sl) 2016-07-29
EP2626417B1 (en) 2015-09-02
DK2626417T3 (en) 2015-11-02
IL236213A (en) 2017-09-28
EP2548951B1 (en) 2016-05-04
HK1160174A1 (en) 2012-08-10
RU2433177C2 (ru) 2011-11-10
WO2007108003A3 (en) 2009-02-12
US20160022738A1 (en) 2016-01-28
EP3091071A1 (en) 2016-11-09
HUE028796T2 (en) 2017-01-30
US20110129447A1 (en) 2011-06-02
SG170761A1 (en) 2011-05-30
PL2548951T3 (pl) 2016-08-31
AU2007228341B2 (en) 2013-10-17
JP5766041B2 (ja) 2015-08-19
EP2010647A2 (en) 2009-01-07
ES2549528T3 (es) 2015-10-29
JP5941454B2 (ja) 2016-06-29
KR20080110831A (ko) 2008-12-19
KR20140136045A (ko) 2014-11-27
CA2646384A1 (en) 2007-09-27
JP2011219486A (ja) 2011-11-04
RU2008141894A (ru) 2010-05-10
EP2626417A1 (en) 2013-08-14
HRP20160538T1 (hr) 2016-07-15

Similar Documents

Publication Publication Date Title
KR101490449B1 (ko) 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지
US20110171182A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US10722541B2 (en) Methods for treating radiation or chemical injury
US20110293583A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
CN101558151B (zh) 细胞扩增方法和藉此产生的细胞和条件培养基用于治疗的用途
HK1177759B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1187950B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1160174B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1136846B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081017

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130625

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140121

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130625

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140421

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140121

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101002336

Request date: 20140421

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140421

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140421

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130925

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140620

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141016

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20150116

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20140522

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150202

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190109

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190109

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20200107

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20200107

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210106

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220106

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20230104

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240103

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20250102

Start annual number: 11

End annual number: 11